Elixinol launches CBD, melatonin blend for sleep support
Elixinol launched Good Night CBD Capsules featuring 15 mg of full-spectrum CBD and 2 mg of melatonin and blended with coconut oil to support a healthy sleep cycle.
Image courtesy of Elixinol
Elixinol (Westminster, CO) launched Good Night CBD Capsules featuring 15 mg of full-spectrum CBD and 2 mg of melatonin and blended with coconut oil to support a healthy sleep cycle.
“Many of our customers already use our products to help them relax, unwind, and ready their bodies for sleep,” said Tom Siciliano, CEO, Americas, at Elixinol, in a press release. “That said, we wanted to create a capsule that specifically addresses sleep. We were very thoughtful when we formulated this product and took a research-backed approach to the amount of melatonin. There is a lot of data suggesting that taking more than 5 mg of melatonin for the average person will likely result in grogginess and could even have the opposite effect and cause sleeplessness.”
Good Night Capsules use a full-spectrum hemp extract, with offers a range of cannabinoids, flavonoids, and terpenes.
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
